Oestrogen and progestin increased urge and stress incontinence in postmenopausal women with coronary heart disease
- oestrogen replacement therapy
- oestrogens (conjugated [USP])
- medroxyprogesterone 17 acetate
- urinary incontinence
Q In postmenopausal women with coronary heart disease, does oestrogen and progestin treatment affect the risk of stress and urge urinary incontinence (UI)?
METHODS
Design:
secondary analysis of a randomised placebo controlled trial (Heart Estrogen/progestin Replacement Study [HERS]).
Allocation:
{concealed}.*
Blinding:
blinded {patients, investigators, and outcome assessors}.*
Follow up period:
4–48 months.
Setting:
20 clinical centres in the US.
Patients:
1228 postmenopausal women <80 years of age who had coronary heart disease, an intact uterus, and reported no episodes of UI within the past week. {Exclusion criteria included use of oral, parenteral, vaginal, or transdermal hormones within 3 months; intolerance to hormone therapy; fasting blood sugar concentration ⩾300 mg/dl; serum triglyceride concentration ⩾300 mg/dl; serum glutamic oxaloacetic transaminase >1.2 times normal; history of …
